In the phase 4, real-world Teri-PRO study, teriflunomide improved treatment satisfaction regardless of age in relapsing MS patients switching from other disease-modifying therapies (DMTs). Improvements occurred as early as week 4 and persisted at week 48 of treatment .
The presented subanalysis of Teri-PRO assessed changes in treatment satisfaction over 48 weeks in relapsing MS patients, stratified by age, who switched to teriflunomide 14 mg from prior DMTs. Four groups were identified:
- ≤35 years (n=85);
- >35 to ≤45 years (n=167);
- >45 to ≤55 years (n=175); and
- >55 years (n=129).
Patients rated their satisfaction using the highly-validated Treatment Satisfaction Questionnaire for Medication (TSQM), version 1.4. Its 4 domains are: global satisfaction, effectiveness, side effects, and convenience. Scores are between 0 and 100, from lower to higher satisfaction. Assessment was done at baseline, when actually the prior DMT was evaluated, and again at week 48, when patients rated satisfaction over the past 2-3 weeks or since last use of medication.
Least-squares mean change (LS) in each TSQM domain was significantly improved at week 48 compared with baseline in all patients aged >35 years:
- >35 to ≤45 years: global satisfaction, 15.0 (P<0.0001); effectiveness, 6.3 (P=0.0157); side effects, 20.6 (P<0.0001); convenience, 31.6 (P<0.0001).
- >45 to ≤55 years: global satisfaction, 15.4 (P<0.0001); effectiveness, 8.3 (P<0.0001); side effects, 20.4 (P<0.0001; convenience, 31.0 (P<0.0001).
- >55 years: global satisfaction, 11.3 (P=0.0001); effectiveness, 9.3 (P=0.0001); side effects, 11.7 (P<0.0001); convenience, 29.8 (P<0.0001).
In the group of patients aged ≤35 years, improvements in 2 domains reached significance: side effects (26.2, P<0.0001) and convenience (28.7, P<0.0001); the other 2 domains showed a numerical positive trend.
- Coyle P, et al. Treatment Satisfaction Across Age Groups in Patients Who Switched to Teriflunomide: Analysis of the Real-world Teri-PRO Study. MSVirtual 2020, Abstract P1065.
« Safety and efficacy of cladribine, glatiramer acetate, and more Next Article
TERIKIDS trial extension of teriflunomide in paediatric MS »